ArticleAnti-cancer drugs2025

BRD9 promotes the malignant phenotype of thyroid cancer by activating the MAPK/ERK pathway.

Yingcheng Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.